Heart mitochondrial toxicity of antiviral nucleosides

抗病毒核苷的心脏线粒体毒性

基本信息

项目摘要

DESCRIPTION (provided by applicant): The antiretroviral nucleoside analogs used in highly active antiretroviral therapy (HAART) have been associated for some time with cardiovascular as well as other tissue toxicities that appear to be directed at mitochondrial biogenesis. In particular, studies have demonstrated that mitochondrial DNA is depleted during toxicity, suggesting a block in DNA replication. Since the triphospho-forms of these nucleoside analogs have been shown to varying degrees to directly inhibit mitochondrial DNA polymerase, this has generally been promoted as the target of this toxicity. However, as discussed in this proposal, we have shown that one of the HAART components, AZT (Zidovudine) is converted slowly only to AZT-MP and no further, in both isolated heart mitochondria and in the isolated perfused rat heart under conditions in which labeled thymidine is readily converted to labeled TTP in both models. Thus it seems unlikely that the toxicity of AZT in the heart is mediated by AZT-TP inhibition of polymerase. Rather, we have shown that the presence of AZT, perhaps via AZT-MP, is a potent inhibitor of thymidine phosphorylation in both isolated heart mitochondria and in the isolated perfused heart. These data suggest an alternative hypothesis that the toxicity of AZT and perhaps other analogs, is caused by their interference with the metabolism of endogenous deoxynucleosides disrupting the substrate supply of dNTPs for mitochondrial DNA replication. This grant has three major goals. The first goal is to document and quantitate the uptake and conversion of each of the endogenous deoxynucleosides, and each of the nucleoside analogs used in HAART therapy, to their tri-phospho-forms in isolated heart mitochondria and in the isolated perfused rat heart. From these data we can determine the relative role of the mitochondria in the conversion process and we can estimate the levels of the various analog intermediates and determine if there is sufficient synthesis of the triphosphate to inhibit the mitochondrial polymerase. The second goal of this proposal is to evaluate the effect of these same nucleoside analogs on the uptake and phosphorylation of the endogenous deoxynucleosides in isolated heart mitochondria and in the isolated perfused heart. The third goal is to evaluate the effect of combination drug therapy on analog and endogenous deoxynucleoside phosphorylation. From this work we hope to identify both the potential toxic form of the nucleoside analog as well as its potential enzymatic target.
描述(由申请人提供): 用于高效抗逆转录病毒治疗(HAART)的抗逆转录病毒核苷类似物与心血管和其他似乎针对线粒体生物发生的组织毒性有关已有一段时间。特别是,研究表明,线粒体DNA在毒性过程中会耗尽,这表明DNA复制受阻。由于这些核苷类似物的三磷酸形式已被证明不同程度地直接抑制线粒体DNA聚合酶,这通常被视为这种毒性的靶标。然而,正如在本提案中讨论的那样,我们已经证明了HAART的一个成分AZT(齐多夫定)在两种模型中都只缓慢地转化为AZT-MP,而在分离的心脏线粒体和隔离的灌流大鼠心脏中没有进一步的转化,在这两种模型中标记的胸腺嘧啶核苷很容易转化为标记的TTP。因此,AZT对心脏的毒性似乎不太可能是由AZT-TP抑制聚合酶介导的。相反,我们已经证明,AZT的存在,可能通过AZT-MP,是分离的心脏线粒体和分离的灌流心脏中胸苷磷酸化的有效抑制物。这些数据提出了另一种假设,即AZT和其他类似物的毒性是由于它们干扰内源性脱氧核苷的代谢,扰乱了线粒体DNA复制所需的dNTPs的底物供应。这笔赠款有三个主要目标。第一个目标是记录和量化在HAART治疗中使用的每个内源性脱氧核苷和每个核苷类似物在分离的心脏线粒体和分离的灌流大鼠心脏中摄取和转化为它们的三磷形式。根据这些数据,我们可以确定线粒体在转化过程中的相对作用,我们可以估计各种模拟中间体的水平,并确定是否有足够的三磷酸合成来抑制线粒体聚合酶。这项建议的第二个目标是评估这些相同的核苷类似物对分离的心脏线粒体和分离的灌流心脏摄取和磷酸化内源性脱氧核苷的影响。第三个目标是评估联合药物治疗对类似物和内源性脱氧核苷磷酸化的影响。通过这项工作,我们希望确定核苷类似物的潜在毒性形式以及其潜在的酶靶标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Edward E. McKee其他文献

Phosphorylation of thymidine and AZT in heart mitochondria
  • DOI:
    10.1385/ct:4:2:155
  • 发表时间:
    2004-06-01
  • 期刊:
  • 影响因子:
    3.700
  • 作者:
    Edward E. McKee;Alice T. Bentley;Matthew Hatch;Joel Gingerich;Delia Susan-Resiga
  • 通讯作者:
    Delia Susan-Resiga
The metabolism of pyrimidine deoxyribonucleosides in isolated heart mitochondria
  • DOI:
    10.1016/j.mito.2006.08.053
  • 发表时间:
    2006-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Darcy D. LaClair;Alice T. Bentley;Edward E. McKee
  • 通讯作者:
    Edward E. McKee
Pyrimidine deoxyribonucleoside and nucleoside-reverse transcriptase inhibitor metabolism in the perfused rat heart
  • DOI:
    10.1016/j.mito.2006.08.052
  • 发表时间:
    2006-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Gerald W. Morris;Matt Doherty;Edward E. McKee
  • 通讯作者:
    Edward E. McKee
41. Origin of the dCTP and TTP Pools in the Isolated Perfused Rat Heart: Implications of TTP Deficiency
  • DOI:
    10.1016/j.mito.2008.12.036
  • 发表时间:
    2009-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Edward E. McKee;Gerald Morris
  • 通讯作者:
    Gerald Morris

Edward E. McKee的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Edward E. McKee', 18)}}的其他基金

Metabolism and toxicity of NRTIs in non-replicating tissues
NRTI 在非复制组织中的代谢和毒性
  • 批准号:
    8500427
  • 财政年份:
    2010
  • 资助金额:
    $ 29.62万
  • 项目类别:
Metabolism and toxicity of nucleoside reverse transcriptase inhibitors in non-rep
非代表中核苷逆转录酶抑制剂的代谢和毒性
  • 批准号:
    8063847
  • 财政年份:
    2010
  • 资助金额:
    $ 29.62万
  • 项目类别:
Metabolism and toxicity of nucleoside reverse transcriptase inhibitors in non-rep
非代表中核苷逆转录酶抑制剂的代谢和毒性
  • 批准号:
    7930391
  • 财政年份:
    2010
  • 资助金额:
    $ 29.62万
  • 项目类别:
Metabolism and toxicity of NRTIs in non-replicating tissues
NRTI 在非复制组织中的代谢和毒性
  • 批准号:
    8240387
  • 财政年份:
    2010
  • 资助金额:
    $ 29.62万
  • 项目类别:
Heart mitochondrial toxicity of antiviral nucleosides
抗病毒核苷的心脏线粒体毒性
  • 批准号:
    6665354
  • 财政年份:
    2002
  • 资助金额:
    $ 29.62万
  • 项目类别:
Heart mitochondrial toxicity of antiviral nucleosides
抗病毒核苷的心脏线粒体毒性
  • 批准号:
    6923682
  • 财政年份:
    2002
  • 资助金额:
    $ 29.62万
  • 项目类别:
Heart mitochondrial toxicity of antiviral nucleosides
抗病毒核苷的心脏线粒体毒性
  • 批准号:
    6785398
  • 财政年份:
    2002
  • 资助金额:
    $ 29.62万
  • 项目类别:
Heart mitochondrial toxicity of antiviral nucleosides
抗病毒核苷的心脏线粒体毒性
  • 批准号:
    7106786
  • 财政年份:
    2002
  • 资助金额:
    $ 29.62万
  • 项目类别:
Mitochondrial Toxicity of Antiviral Nucleosides
抗病毒核苷的线粒体毒性
  • 批准号:
    7851315
  • 财政年份:
    2002
  • 资助金额:
    $ 29.62万
  • 项目类别:
Heart mitochondrial toxicity of antiviral nucleosides
抗病毒核苷的心脏线粒体毒性
  • 批准号:
    7080433
  • 财政年份:
    2002
  • 资助金额:
    $ 29.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了